1.6万 件 ・ 関連度順
Drug and chemical toxicity assessment via adverse outcome pathways (AOPs), real-world FAERS adverse event signals, FDA labels, and toxicogenomic associations. Triangulates molecular initiating event to cellular outcome to organ-level toxicity to clinical adverse event. Use for hepatotoxicity/cardiotoxicity/nephrotoxicity prediction and toxicology reports.
日本語の概要は準備中です。原文の説明を表示しています。
Trace drug mechanism of action — primary target → downstream signaling → pathway perturbation → tissue/organ effect → clinical outcome. Uses DrugBank, ChEMBL, KEGG, Reactome, STRING. Use for understanding how a drug works, identifying off-target effects, mechanism-based combination therapy design, and writing mechanism sections of reports.
日本語の概要は準備中です。原文の説明を表示しています。
Assess drug-drug interactions — CYP metabolic interactions (substrate/inhibitor/inducer), transporter (P-gp, BCRP, OATP) effects, pharmacodynamic synergy/antagonism, clinical significance scoring, and management recommendations. Use for polypharmacy review, prescribing decision support, and safety analysis when adding or switching drugs.
日本語の概要は準備中です。原文の説明を表示しています。
Comprehensive ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) profiling for drug candidates. Integrates ADMET-AI predictions, SwissADME drug-likeness, PubChemTox experimental toxicity, ChEMBL clinical data, Lipinski rule-of-five, and CYP interaction data. Use for drug-likeness assessment, BBB penetration, bioavailability, hepatotoxicity prediction, ADME/PK profiling, or screening compound libraries before lab testing.
日本語の概要は準備中です。原文の説明を表示しています。
Identify drug repurposing candidates via target-based, compound-based, and disease-based strategies. Combines drug-target-disease network reasoning with mechanism rationale, clinical-trial precedent, and patent/regulatory feasibility. Use for hypothesis-generating repurposing for orphan diseases, finding existing drugs for new indications, and prioritizing candidates by evidence and feasibility.
日本語の概要は準備中です。原文の説明を表示しています。
Compound-target-disease network construction and analysis for drug repurposing, polypharmacology discovery, and multi-target drug design. Uses STRING, BioGRID, ChEMBL, DGIdb, OMIM, OpenTargets. Use for off-target effect prediction, network-based drug repurposing, and identifying molecules with desired multi-target profile.
日本語の概要は準備中です。原文の説明を表示しています。
Code quality patterns and guidelines for ToolUniverse tool development. Apply when writing, fixing, or refactoring tool Python code in the ToolUniverse project. Encodes lessons from 80+ debug rounds. Use alongside devtu-fix-tool and devtu-self-evolve. Triggers: implementing tool fixes, writing new tool classes, reviewing tool code quality, checking schema correctness, looking up API-specific bug fixes.
日本語の概要は準備中です。原文の説明を表示しています。
Metabolomics pathway analysis — metabolite identification (HMDB, KEGG, ChEBI), pathway mapping (Reactome, KEGG, MetaCyc), disease associations, enzyme/gene linkage. Use for metabolite-to-pathway-to-disease connections, BridgeDb-based ID conversion, and integrating metabolomics with gene-level pathway analyses.
日本語の概要は準備中です。原文の説明を表示しています。
Dose-response / concentration-response curve fitting — IC50, EC50, Hill slope, Emax/Emin efficacy, and relative potency from paired concentration vs response data (enzyme/cell assays, drug screening, agonist/antagonist pharmacology). Fits the 4-parameter logistic (Hill sigmoidal) model. Use when you have concentrations + responses and need a potency value, to compare two compounds' potency, or to judge curve quality. NOT for image-derived dose-response (use tooluniverse-image-analysis) and NOT for survival/regression (use tooluniverse-statistical-modeling).
日本語の概要は準備中です。原文の説明を表示しています。
Performs ML-based protein-ligand pose prediction and scoring using DiffDock-L (diffusion-based), Boltz-1 / Boltz-2 (foundation model with affinity), Chai-1, AlphaFold3 ligand, EquiBind, TANKBind, NeuralPLexer, and hybrid workflows (DiffDock pose + GNINA rescore + PoseBusters QC). Explicit handling of when ML beats classical docking, when classical beats ML, the PB-invalid pose problem, and rescoring as the standard production hybrid. Use when modern docking is needed: foundation-model ligand-pose prediction, AI rescoring of classical poses, or scaffold-hopping in cross-docking scenarios.
日本語の概要は準備中です。原文の説明を表示しています。
Builds QSAR / QSPR models using chemprop D-MPNN, MolFormer, Uni-Mol, ChemBERTa, random forest baselines, and Gaussian processes with explicit handling of OECD 5 principles, applicability domain (kNN, leverage, conformal prediction, Mahalanobis), scaffold-balanced splits, ensemble uncertainty, calibration (Platt, isotonic), feature importance (SHAP, atomic attribution), and prospective validation. Use when building target-specific predictive models from in-house bioassay data, ADMET endpoints, or selectivity profiles.
日本語の概要は準備中です。原文の説明を表示しています。
Multi-method binding pocket detection and druggability assessment. Grid-based, fpocket, and P2Rank detection with druggability scoring, visualization, and cross-structure comparison.
日本語の概要は準備中です。原文の説明を表示しています。
Performs structure-based virtual screening using AutoDock Vina, SMINA, GNINA (CNN scoring), and DiffDock-L hybrid workflows with explicit choice rules across rigid vs flexible docking, cross-docking vs self-docking, binding-site detection (P2Rank, fpocket), receptor preparation (PDB2PQR, PROPKA), ligand preparation (meeko, OpenBabel), and ultralarge-library screening (ZINC22, Enamine REAL). Use when screening chemical libraries against a protein target to find candidate binders, ranking docking poses, or selecting a docking workflow for a specific scenario.
日本語の概要は準備中です。原文の説明を表示しています。
Assigns honest lipid annotation levels, designs class-based internal-standard quantification, and runs lipid-aware differential and enrichment analysis with lipidr, guarding against in-source-fragment phantoms, sn-position over-claims, and invalid cross-class quantification. Use when naming or canonicalizing lipid species (shorthand separators, Goslin), deciding shotgun vs RP vs HILIC LC-MS, picking internal standards (SPLASH/EquiSPLASH), interpreting MS-DIAL/LipidSearch output, or comparing lipid classes. For general feature detection see metabolomics/xcms-preprocessing and metabolomics/msdial-preprocessing; for non-lipid annotation confidence see metabolomics/metabolite-annotation; for normalization/QC see metabolomics/normalization-qc; for multivariate stats see metabolomics/statistical-analysis.
日本語の概要は準備中です。原文の説明を表示しています。
Automated LLM-driven hypothesis generation and testing on tabular datasets. Use when you want to systematically explore hypotheses about patterns in empirical data (e.g., deception detection, content analysis). Combines literature insights with data-driven hypothesis testing. For manual hypothesis formulation use hypothesis-generation; for creative ideation use scientific-brainstorming.
日本語の概要は準備中です。原文の説明を表示しています。
Predicts ADMET properties using ADMETlab 3.0 (119 endpoints with uncertainty), ADMET-AI, DeepChem MolNet, and chemprop D-MPNN with explicit handling of OECD QSAR principles, applicability domain assessment, calibration, hERG/CYP/AMES gold-standard endpoints, and PAINS / Lipinski / Ro5 / Veber / BBB druglikeness filters. Use when filtering compounds for drug-likeness, prioritizing leads by predicted safety, or building an in-house ADMET QSAR model.
日本語の概要は準備中です。原文の説明を表示しています。
Interpretable ADMET analysis with mechanistic reasoning. Maps liabilities to structural causes and biological pathways. Based on CoTox (Park 2025) and DrugR (Liu 2026).
日本語の概要は準備中です。原文の説明を表示しています。
Multi-document tabs with AdwTabView/TabBar/TabOverview — tab menus, pinning, keyboard shortcuts. Use when an app opens multiple documents or sessions in tabs.
日本語の概要は準備中です。原文の説明を表示しています。
GitHub Actions CI/CD for GNOME apps — build+test with GTK4/libadwaita on runners, Flatpak builds via flatpak-github-actions, attaching .flatpak bundles to releases, optional OCI publishing to GHCR, and headless GUI smoke tests with Xvfb/AT-SPI. Use when setting up CI, release automation, or GUI testing for a GTK app.
日本語の概要は準備中です。原文の説明を表示しています。
Evaluate an interface from a UX perspective, assessing hierarchy, information architecture, emotional resonance, cognitive load, and overall quality with evidence-linked judgments and actionable feedback. Use when the user wants an overall design or UX review—not when the main need is measurable accessibility/performance diagnosis, or final micro-detail polish.
日本語の概要は準備中です。原文の説明を表示しています。
Improve interface resilience through better error handling, i18n support, text overflow handling, and edge case management, making interfaces robust and production-ready. Use when the user asks to harden, make production-ready, handle edge cases, add error states, or fix overflow and i18n issues.
日本語の概要は準備中です。原文の説明を表示しています。
Facilitate interactive brainstorming sessions using diverse creative techniques and ideation methods. Use when the user says help me brainstorm or help me ideate.
日本語の概要は準備中です。原文の説明を表示しています。
Stellar Assets (classic) + trustlines + Stellar Asset Contract (SAC) bridge to smart contracts. Covers asset issuance, distribution, authorization flags, clawback, regulated assets, trustline management, and the SAC interop layer that exposes classic assets as SEP-41 contract tokens. Use when tokenizing real-world assets, issuing stablecoins, managing trustlines, or bridging classic assets to smart contracts.
日本語の概要は準備中です。原文の説明を表示しています。
Meta-skill — browse and discover all installed stellar.new skills. Use when a user says "what skills do I have", "show me available skills", "what can I do", "find a skill for X", "which skill should I use", "help me navigate", "what does stellar.new do", or "where do I start". Lists skills by journey phase, surfaces the SKILL_ROUTER trigger phrases, and recommends the next skill given current context.
日本語の概要は準備中です。原文の説明を表示しています。